Such alterations have been identified in relation to the familial AD causing mutations in the APP gene, such as the London and Swedish mutations, known to cause increased Aβ42/Aβ40 ratio, highlighting the potential link between glycosylation and AD pathogenesis (Schedin-Weiss et al., 2014). Here, APP is linked to Alzheimer disease.